09359443 cites 178 patents.

Disclosed are compositions and methods comprising combinations of anti-CD74 and anti-CD20 antibodies or antigen-binding fragments thereof. The antibody combination may also be used with a therapeutic agent that is attached to antibody or fragment thereof or separately administered. The therapeutic agent may be an immunomodulator, a cytokine, a toxin or other known therapeutic agent. Preferably, the anti-CD74 and anti-CD20 antibody or fragment are part of a DNL complex. More preferably, combination therapy with the anti-CD74 and anti-CD20 antibody or fragment is more effective than either antibody alone, or the combination of unconjugated antibodies. Administration of combination induces apoptosis of target cells in diseases in which CD74 is overexpressed, such as solid tumors, B-cell lymphomas or leukemias, autoimmune disease, immune dysfunction disease or diabetes. Preferably, the target cells are B cells.

Title
Combination therapy with anti-CD74 and anti-CD20 antibodies provides enhanced toxicity to B-cell diseases
Application Number
14/520596
Publication Number
9359443 (B2)
Application Date
October 22, 2014
Publication Date
June 7, 2016
Inventor
Edmund A Rossi
Woodland Park
NJ, US
David M Goldenberg
Mendham
NJ, US
Chien Hsing Chang
Downingtown
PA, US
Agent
Richard A Nakashima
Assignee
IBC Pharmaceuticals
NJ, US
IPC
A61K 38/21
C07K 14/47
A61K 51/10
A61K 38/19
A61K 39/395
A61K 47/48
C07K 16/28
View Original Source